Page 99 - Tyrosine-Based Bioconjugations - Jorick Bruins

Abstract:
While termini of antibodies are easily modified, their pharmacokinetic profile is generally inferior to conjugates on internal amino acid residues. Therefore, an internal exposed tyrosine residue was introduced via solvent-accessible loops on the CDR and the Fc-region. Labeling on the CDR- tyrosine went quantitatively, and labeling could be inhibited by co-inhibition with the corresponding anti-idiotypic antibody. Labeling on the Fc-tyrosine was also achieved, though the antibody proved instable overtime.